What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GIP / GLP-1 dual receptor agonist
PeptideXpo buyer fit
This page is written for buyers comparing Tirzepatide inside a broader peptide sourcing program: distributor assortment, repeat-order economics, custom fill ladders, and whether one supplier can support multiple GLP-1 SKUs without a separate qualification cycle for every molecule. Compounding-pharmacy release-package qualification belongs to a dedicated regulated-pharmacy channel; this PeptideXpo page owns the catalog and commercial sourcing comparison.
Overview
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a balanced dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The molecule incorporates a C20 fatty-diacid moiety on a Lys side chain that drives albumin binding and gives the once-weekly pharmacokinetic profile that distinguishes it from earlier GLP-1 mono-agonists. As an active ingredient, Tirzepatide is the basis of the FDA-approved finished drug under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). PeptideXpo supplies lyophilized Tirzepatide acetate at ≥99.0% HPLC purity, with batch-specific COA covering peak-integration HPLC, ESI mass-spec identity within 0.5 Da of theoretical, water content by Karl Fischer, and counter-ion quantitation. Sequence verification by LC-MS/MS is available on request and recommended for first-time qualification of a new supplier. The catalog vial range, 2 mg through 120 mg, 12 standard fills, is the broadest in our catalog and accommodates everything from pilot research aliquots to 503A / 503B compounding pharmacy workflows. Custom fills and sterile-filled vials are available through the OEM service.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit. The Tirzepatide finished drug is FDA-approved (Mounjaro / Zepbound); the bulk active itself is not currently on the 503A bulks list, and compounding eligibility depends on the destination market's current shortage / regulatory posture, which buyers are responsible for verifying at the time of dispense.
Frequently asked questions
Tirzepatide CAS is 2023788-19-2. Molecular formula C225H348N48O68, average MW 4813.45 g/mol. The molecule is a 39-amino-acid synthetic peptide with a C20 fatty-diacid albumin-binding moiety; the full identity reference (sequence, CAS, formula, MW) travels on every batch COA.
Both are once-weekly fatty-acid-conjugated peptide GLP-1-pathway agonists, but the receptor profiles differ: Semaglutide is a selective GLP-1 mono-agonist, while Tirzepatide is a balanced GIP / GLP-1 dual agonist. Sequence-wise Tirzepatide is 39 amino acids vs. Semaglutide's 31, and the fatty-acid linker geometry is different (C20 diacid on Tirzepatide vs. C18 diacid on Semaglutide). In clinical readouts the dual mechanism produces larger HbA1c and weight reductions than the GLP-1 mono-agonist class at comparable exposures.
Tirzepatide ships as the acetate salt by default. Acetate is preferred over TFA for downstream pharmaceutical and compounding use because residual TFA can suppress observed potency in cell-based and binding assays and complicates removal in finished formulations. TFA-salt material can be supplied on explicit request, but most compounding pharmacy and research buyers should default to acetate.
Standard fills range from 2 mg to 120 mg per vial, 12 sizes in total (2, 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, 120 mg). Compounding pharmacies most commonly order 5 mg, 10 mg, 15 mg, and 20 mg fills for finished-dose preparation; research labs typically buy 2 mg or 5 mg. Custom fill volumes, sterile-filled vials under ISO 7/8 cleanroom conditions, and pre-blended Tirzepatide-plus-cagrilintide combinations are available through the OEM service.
Related peptides
